ESALY: Eisai insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Clinical trial readouts
6 Phase 2 or 3 trials by Eisai with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-12-03 (est.) | E2814 | Alzheimer's Disease | Phase 2 | 105 | Enrollment complete | NCT06602258 |
| 2026-12-31 (est.) | Lecanemab IV | Early Alzheimer's Disease | Phase 3 | 1,906 | Enrollment complete | NCT03887455 |
| 2027-02-14 (est.) | E2086 | Narcolepsy | Phase 2 | 64 | Recruiting | NCT07493265 |
| 2027-03-31 (est.) | E7389-LF | Solid Neoplasms | Phase 1/2 | 125 | Enrollment complete | NCT04078295 |
| 2027-03-31 (est.) | E7386 | Endometrial Neoplasms | Phase 1/2 | 301 | Enrollment complete | NCT04008797 |
| 2027-04-06 (est.) | Perampanel Oral Suspension | Pediatric Epileptic Syndrome | Phase 2 | 100 | Enrollment complete | NCT04015141 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.